BJU International最新文献

{"title":"Spatial distribution and subtype‐specific expression patterns of Nectin‐4 in muscle‐invasive bladder cancer","authors":"Csilla Olah, Lara Sichward, Boris Hadaschik, Christopher Darr, Viktor Grünwald, Ulrich Krafft, Barbara T. Grünwald, Osama Mahmoud, Mulham Al‐Nader, Peter Nyirady, Henning Reis, Tibor Szarvas","doi":"10.1111/bju.16643","DOIUrl":"https://doi.org/10.1111/bju.16643","url":null,"abstract":"ObjectiveTo investigate the expression patterns of Nectin‐4, the target molecule of the antibody‐drug conjugate enfortumab vedotin (EV), in relation to histological and molecular subtypes of urothelial bladder cancer (UBC).Patients and MethodsWe assessed the protein expression patterns of Nectin‐4 in a spatially organised tissue microarray containing 1386 tissue cores from 314 consecutive patients with UBC who underwent radical cystectomy (2005–2018). Results were correlated with clinicopathological and follow‐up data, as well as with different spatial locations (tumour central vs tumour‐normal interface and primary tumour vs lymph node [LN] metastases). Additionally, we correlated Nectin‐4 expression levels with histological and molecular subtypes. Finally, we assessed the value of Nectin‐4 expression for predicting the efficacy of platinum therapy in the peri‐operative setting.ResultsNectin‐4 expression was observed in 63% of primary tumours and 87% of LN metastases, with significantly higher levels in LNs. Of the histological subtypes, the micropapillary (58%) and pure urothelial histologies (30%) were associated with the highest Nectin‐4 positivity, while the sarcomatoid (17%), squamous (15%) and small/cell‐neuroendocrine (0%) subtypes exhibited the lowest. Nectin‐4 immunopositivity rates were significantly higher in luminal (urothelial‐like [42%] and genomically unstable [34%] Lund subtypes) compared to the basal (5%) or mesenchymal (0%) molecular subtypes. Higher Nectin‐4 expression levels were associated with lower tumour stage but showed no association with overall survival. Finally, patients with low Nectin‐4 expression tended to derive more benefit from platinum‐based chemotherapy in both adjuvant and neoadjuvant settings (<jats:italic>P</jats:italic> &lt; 0.001, <jats:italic>P</jats:italic> = 0.067).ConclusionOur results revealed a low spatial heterogeneity of Nectin‐4 expression within the primary tumour. In contrast, differential Nectin‐4 expression was found in the context of histological and molecular subtypes. Nectin‐4‐expressing tumours may show varying sensitivity to both EV and platinum‐based chemotherapy.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"2 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results","authors":"Pietro Scilipoti, Mattia Longoni, Mario de Angelis, Paolo Zaurito, Albane Massiet, Daniele Dutto, Francesco Soria, Mario Álvarez-Maestro, Alfredo Aguilera Bazán, Benjamin Pradere, Tobias Klatte, Roberto Contieri, Rodolfo Hurle, Wojciech Krajewski, José Daniel Subiela, Renate Pichler, Aleksandra Szostek, Gautier Marcq, José Luis Rodríguez Elena, Javier Aranda, Paolo Gontero, Morgan Rouprêt, Shahrokh F. Shariat, Andrea Necchi, Francesco Montorsi, Alberto Briganti, Evanguelos Xylinas, Marco Moschini, , ","doi":"10.1111/bju.16645","DOIUrl":"https://doi.org/10.1111/bju.16645","url":null,"abstract":"To evaluate the oncological efficacy and safety of sequential intravesical gemcitabine/docetaxel (Gem/Doce) therapy in a European cohort of patients with high-risk and very-high-risk non-muscle-invasive bladder cancer (NMIBC) after previous Bacillus Calmette–Guérin (BCG) treatment.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"26 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142961895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a randomised trial","authors":"Meryam El Issaoui,&nbsp;Marlene Elmelund,&nbsp;Niels Klarskov","doi":"10.1111/bju.16647","DOIUrl":"10.1111/bju.16647","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate the effect of intravesical alkalinised lidocaine as an anaesthetic treatment on procedural pain during intradetrusor onabotulinumtoxinA (BTX-A) injections for overactive bladder.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and Methods</h3>\u0000 \u0000 <p>This single-centre, randomised, double-blind, placebo-controlled two period crossover trial was conducted on women scheduled for BTX-A injections at our outpatient urogynaecology clinic between September 2022 and May 2024. Patients were randomly assigned (1:1) to receive either alkalinised lidocaine or placebo during the first treatment period. Alkalinised lidocaine solution comprised lidocaine hydrochloride (20 mg/mL, 20 mL), sodium hydrogen carbonate (1 mmoL/mL, 10 mL), and sodium chloride (9 g/L, 10 mL). The matching placebo was sodium chloride (9 g/L, 40 mL). The primary outcome measure was procedural pain rated on a 100-mm visual analogue scale (VAS). Secondary outcomes included adverse effects such as post-void residual urine volumes requiring catheterisation, urinary tract infection, haematuria 1 week after treatment, and patient satisfaction measured on a 5-point scale. During the second treatment period, patients received the alternative intervention.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We enrolled 50 patients, of which 41 were eligible for per-protocol analyses. The mean VAS score was significantly lower following intravesical alkalinised lidocaine (mean 21.3 mm, 95% confidence interval [CI] 14.7–27.8 mm) compared to placebo (mean 41.6 mm, 95% CI 35.0–48.1 mm) with a mean difference of −20.3 mm (95% CI −29.2 to −11.5 mm; <i>P</i> &lt; 0.001). Adverse events and patient satisfaction did not significantly differ between the alkalinised lidocaine and placebo treatments (<i>P</i> = 0.825 and <i>P</i> = 0.138, respectively).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Intravesical instillation of alkalinised lidocaine before BTX-A injections significantly reduced VAS pain scores compared to placebo (ClinicalTrials.gov identifier: NCT05415865).</p>\u0000 </section>\u0000 </div>","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"135 4","pages":"638-647"},"PeriodicalIF":3.7,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bju.16647","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142961227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of serum and plasma microRNA expression levels in patients with germ cell tumours","authors":"Fady Baky, Richard S. Matulewicz, Andrea Knezevic, Jahwa Hossain, Brandon Williams, Anna Lee, Joel Sheinfeld, Nicole Liso, Rachel So, Alisa Valentino, Fei Ye, Samuel A. Funt, Darren R. Feldman","doi":"10.1111/bju.16644","DOIUrl":"https://doi.org/10.1111/bju.16644","url":null,"abstract":"Click on the article title to read more.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"14 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142940341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating choices: understanding the decision-making journey of patients with localised kidney cancer","authors":"Katharina Beyer, Lionne D.F. Venderbos, Monique J. Roobol, Rachel H. Giles, Paul Verhagen, Ravi Barod, Lisa M. Wintner, Michael A.S. Jewett, Mieke Van Hemelrijck, Netty Kinsella","doi":"10.1111/bju.16635","DOIUrl":"https://doi.org/10.1111/bju.16635","url":null,"abstract":"To explore patients’ experience of decision making regarding treatment of localised kidney cancer.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"14 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142935825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta-analysis","authors":"David C. Chen, Siyu Huang, Nathan Papa, Shankar Siva, Damien M. Bolton, Nathan Lawrentschuk, Louise Emmett, Declan G. Murphy, Michael S. Hofman, Marlon L. Perera","doi":"10.1111/bju.16608","DOIUrl":"https://doi.org/10.1111/bju.16608","url":null,"abstract":"To perform a systematic review and meta-analysis to assess the relationship between intraprostatic maximum standardised uptake value (SUV_max) of the dominant prostatic lesion as measured on preoperative prostate-specific membrane antigen (PSMA) positron emission tomography (PET) with radical prostatectomy International Society of Urological Pathology (ISUP) Grade Group, pathological tumour (pT) staging, and biochemical recurrence (BCR).","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"28 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142935107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HKUA ASM 2024 abstracts","authors":"","doi":"10.1111/bju.16603","DOIUrl":"10.1111/bju.16603","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"135 S1","pages":"4-30"},"PeriodicalIF":3.7,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bju.16603","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142937057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"‘BJUI Clinical Dilemma’: the incidental small renal mass in a solitary kidney","authors":"Bruce Gao,&nbsp;Pratik Kanabur,&nbsp;Riccardo Campi,&nbsp;Maxine Tran,&nbsp;Jaime Landman,&nbsp;Ivan Pedrosa,&nbsp;Ben Challacombe,&nbsp;Tze Min Wah,&nbsp;Shankar Siva,&nbsp;Michael Jewett,&nbsp;Grant D. Stewart,&nbsp;Brian Shuch,&nbsp;Ralph Clayman","doi":"10.1111/bju.16627","DOIUrl":"10.1111/bju.16627","url":null,"abstract":"&lt;p&gt;The incidental small renal mass (SRM; ≤4 cm; clinical T stage [cT]1a) has become increasingly common due to the widespread utilisation of ultrasonography and cross-sectional imaging. Today, most such patients present with asymptomatic, localised disease that can be surgically treated with curative intent; however, up to 25% of SRMs are benign [&lt;span&gt;1&lt;/span&gt;]. This creates a clinical dilemma: balancing the removal of malignant tumours with avoiding needless active treatment for benign masses.&lt;/p&gt;&lt;p&gt;This ‘&lt;i&gt;BJUI&lt;/i&gt; Clinical Dilemma’ presents a structured format to address the common clinical presentation of a SRM through a case vignette approach. Following the vignette, leading experts will provide brief commentary, explaining the rationale behind their preferred management strategies. This approach encourages a balanced, expert-driven discussion on alternative strategies, offering readers insights into decision-making processes for common, yet nuanced cases in urological practice.&lt;/p&gt;&lt;p&gt;A 63-year-old man presented to his primary care physician with an incidental CT finding of a 2.9-cm left renal mass in a congenital solitary left kidney, something the patient was previously unaware of, as part of an emergency room evaluation for brief epigastric pain—now completely resolved. He is an unmarried schoolteacher. He is overweight (body mass index of 29.7 kg/m&lt;sup&gt;2&lt;/sup&gt;) and has well-controlled hypertension (on atenolol). He denies any history of smoking or occupational exposures and has no relevant family history.&lt;/p&gt;&lt;p&gt;He denies any urinary symptoms, haematuria, flank pain, weight loss, or constitutional symptoms. His blood pressure is within the normal range, and physical examination reveals moderate central abdominal adiposity without any palpable masses or surgical scars.&lt;/p&gt;&lt;p&gt;A full blood count and comprehensive metabolic panel are normal; urine analysis is unremarkable. Creatinine is 88 μmol/L and estimated GFR (eGFR) is 75 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;.&lt;/p&gt;&lt;p&gt;A contrast-enhanced CT scan was performed, including images without and with contrast during the arterial phase, revealing a 2.9 × 2.7 cm enhancing, exophytic renal mass arising from the posterior interpolar region of the left kidney (Radius, Exophytic/Endophytic, Nearness to collecting system or sinus, Anterior/Posterior, Location [R.E.N.A.L.] nephrometry score 8; Fig. 1). The mass briskly enhances, is well-defined, and appears to be predominantly solid. There are no signs of sinus, renal vein or perinephric fat invasion and no enlarged regional lymph nodes. The contralateral kidney is absent. A diagnostic chest X-ray was unremarkable.&lt;/p&gt;&lt;p&gt;The patient seeks your opinion as to what would be his best course of action.&lt;/p&gt;&lt;p&gt;This is a complex clinical scenario requiring individualised care, ideally delivered at a referral centre by an experienced multidisciplinary team (MDT). The case has many interconnected decision-points (Table 1) [&lt;span&gt;2, 3&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;The CT characteristics of","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"135 3","pages":"371-379"},"PeriodicalIF":3.7,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bju.16627","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142935138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selective treatment de-escalation in advanced prostate cancer: have we come full circle?","authors":"Bryan Chong, Marniza Saad, Tsung Wen Chong, John Thng, Yu Guang Tan, Kae Jack Tay, Christopher Cheng, Po-Hung Lin, Jeremy Teoh, Peter Ka-Fung Chiu, Nathan Lawrentschuk, Renu Eapen, Declan Murphy, Johan Chan, Melvin L.K. Chua, Jeffrey Tuan, John Yuen, Ravindran Kanesvaran, Kenneth Chen","doi":"10.1111/bju.16632","DOIUrl":"https://doi.org/10.1111/bju.16632","url":null,"abstract":"Compelling evidence has solidified the notion of early treatment intensification in managing patients with metastatic hormone-sensitive prostate cancer (mHSPC). Landmark trials have provided Level 1 evidence for the survival benefits achieved by combining multiple agents. The efficacy of combined therapy relies not only on how treatment is intensified but also on how it is de-escalated. This underscores the importance of tailored treatment approaches, potentially involving a reduction in therapy for specific patients, to strike a balance between the benefits of hormonal treatment and its associated adverse effects. While de-escalation of therapy in mHSPC remains challenging due to limited evidence, it is recommended for elderly or frail patients, those with poor performance status, or experiencing significant toxicity. However, for patients with excellent prostate-specific antigen responses or favourable biomarkers, decisions should be personalised, weighing the potential benefits of continued treatment against the risk of long-term side effects, using risk stratification tools where appropriate.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"132 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142917426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TYTOCARE™ home telemonitoring device after radical cystectomy to optimise postoperative outcomes","authors":"Daniele Amparore, Sabrina De Cillis, Marco Colombo, Valentina Garzena, Michele Sica, Enrico Checcucci, Alberto Piana, Federico Piramide, Alberto Quarà, Matteo Manfredi, Cristian Fiori, Francesco Porpiglia","doi":"10.1111/bju.16637","DOIUrl":"https://doi.org/10.1111/bju.16637","url":null,"abstract":"ObjectivesTo evaluate the role of the TYTOCARE™ telemedicine programme for home telemonitoring during the early postoperative period following radical cystectomy (RC) in a prospective single‐centre study.Materials and MethodsThe study included patients aged &lt;80 years with internet access who underwent RC at our institution between March 2021 and August 2023. Upon discharge, patients were monitored at home using the TYTOCARE™ telemedicine system. Daily, patients completed a symptom questionnaire and recorded heart rate, body temperature, intestinal sounds, and urine output, and wound/ostomy evaluations via photos. Weekly televisits via the TYTOCARE<jats:sup>TM</jats:sup> platform and app were scheduled, with additional controls as needed. After 30 days, patients assessed their satisfaction using a visual analogue scale (VAS; 0–100) and a Telemedicine Satisfaction Questionnaire (TSQ; 1–5) and any technical issues were documented. A control group of patients, who underwent RC in the same study period but who did not take part in a postoperative telemonitoring programme, was chosen for comparison, with analysis of demographics, peri‐operative data, postoperative complications and hospital readmissions within 30 days after discharge.ResultsA total of 16 patients were included in the TYTOCARE<jats:sup>TM</jats:sup> group, and 88 in the control group. The mean VAS satisfaction scores were 86.4 (patients) and 92.3 (healthcare providers). The mean TSQ score was 4.3, indicating high satisfaction. All TYTOCARE<jats:sup>TM</jats:sup> patients reported they would use and recommend the device. Two patients encountered minor technical issues, which were easily resolved. The TYTOCARE<jats:sup>TM</jats:sup> group had a shorter hospital stay (11 vs 14 days; <jats:italic>P</jats:italic> = 0.04) and fewer medical complications ( 2/16 vs 21/88; <jats:italic>P</jats:italic> = 0.02). No TYTOCARE<jats:sup>TM</jats:sup> patients were readmitted within 30 days, compared to 20.4% in the control group.ConclusionThe TYTOCARE<jats:sup>TM</jats:sup> telemonitoring programme seems to be feasible and highly adhered to by patients and caregivers, with reductions in length of hospital stay, medical complications and hospital readmissions within the first 30 days post‐discharge.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"48 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142888104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}